NASDAQ:JAGX Jaguar Animal Health Q1 2026 Earnings Report $2.91 -0.56 (-16.14%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.05 +0.14 (+4.78%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Jaguar Animal Health EPS ResultsActual EPS-$13.60Consensus EPS -$149.10Beat/MissBeat by +$135.50One Year Ago EPSN/AJaguar Animal Health Revenue ResultsActual Revenue$20.27 millionExpected Revenue$4.21 millionBeat/MissBeat by +$16.06 millionYoY Revenue GrowthN/AJaguar Animal Health Announcement DetailsQuarterQ1 2026Date5/20/2026TimeAfter Market ClosesConference Call DateTuesday, May 26, 2026Conference Call Time8:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jaguar Animal Health Earnings HeadlinesJaguar Animal Health (NASDAQ:JAGX) Upgraded to Hold at Wall Street ZenMay 23 at 1:13 AM | americanbankingnews.comJaguar Animal Health Granted Short Nasdaq Compliance ExtensionMay 16, 2026 | theglobeandmail.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 23 at 1:00 AM | Weiss Ratings (Ad)Jaguar Health, Inc.: Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea in DogsApril 30, 2026 | finanznachrichten.deJaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for ...April 24, 2026 | usatoday.comJaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks TranscriptApril 10, 2026 | seekingalpha.comSee More Jaguar Animal Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jaguar Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jaguar Animal Health and other key companies, straight to your email. Email Address About Jaguar Animal HealthJaguar Animal Health (NASDAQ:JAGX) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments. Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding. The company is headquartered in East Windsor, New Jersey, and maintains a streamlined development organization designed to advance lead candidates from proof-of-concept through regulatory approvals and commercial launch. Among Jaguar’s key offerings is a proprietary probiotic formulation intended to reduce the incidence and severity of post-weaning diarrhea in piglets, which has received regulatory clearance in select markets. In parallel, the company is progressing a complementary feed-additive candidate for controlling necrotic enteritis in broiler chickens. Jaguar leverages in-house expertise in microbial therapeutics to optimize dosing regimens and demonstrate consistent performance under commercial farming conditions. To date, Jaguar Animal Health serves customers primarily in Latin America through strategic distribution partnerships, while preparing for broader market entry in North America. The company’s leadership team brings experience in veterinary development, regulatory affairs, and commercial operations, positioning Jaguar to address growing global demand for effective, antibiotic-reducing solutions in livestock production.View Jaguar Animal Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See More Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
